Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H8O2 |
Molecular Weight | 136.1479 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC1=CC=CC=C1
InChI
InChIKey=WLJVXDMOQOGPHL-UHFFFAOYSA-N
InChI=1S/C8H8O2/c9-8(10)6-7-4-2-1-3-5-7/h1-5H,6H2,(H,9,10)
Molecular Formula | C8H8O2 |
Molecular Weight | 136.1479 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB09269Curator's Comment: description was created based on several sources, including:
https://clinicaltrials.gov/ct2/show/NCT00003241?term=Phenylacetic+acid&rank=3
https://en.wikipedia.org/wiki/Phenylacetic_acid
Sources: http://www.drugbank.ca/drugs/DB09269
Curator's Comment: description was created based on several sources, including:
https://clinicaltrials.gov/ct2/show/NCT00003241?term=Phenylacetic+acid&rank=3
https://en.wikipedia.org/wiki/Phenylacetic_acid
Phenylacetic acid (abr. PAA and synonyms are: α-toluic acid, benzeneacetic acid, alpha tolylic acid, 2-phenylacetic acid, β-phenylacetic acid) is an organic compound containing a phenyl functional group and acarboxylic acid functional group. Because it is used in the illicit production of phenylacetone (used in the manufacture of substituted amphetamines), it is subject to controls in countries including the United States and China Phenylacetic acid is used in some perfumes, possessing a honey-like odor in low concentrations, and is also used in penicillin G production. It is also employed to treat type II hyperammonemia to help reduce the amounts of ammonia in a patient's bloodstream by forming phenylacetyl-CoA, which then reacts with nitrogen-rich glutamine to form phenylacetylglutamine. This compound is then secreted by the patient's body. In Phase 2 of clinical research it investigated in the treatment of Brain and Central Nervous System Tumors.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=935645
Curator's Comment: Known to be CNS penetrant in cat. Human data not available.
Labeled phenylacetic acid (14C-PAA) penetrates blood-cerebrospinal fluid (CSF) barrier in cats only under a high gradient of concentration
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | AMMONUL Approved UseSodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. Launch Date2005 |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2225 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15050977/ |
3.75 g/m² single, intravenous dose: 3.75 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: SODIUM BENZOATE |
PHENYLACETIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
3022 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15050977/ |
5.5 g/m² single, intravenous dose: 5.5 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: SODIUM BENZOATE |
PHENYLACETIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
281 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15050977/ |
3.75 g/m² single, intravenous dose: 3.75 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: SODIUM BENZOATE |
PHENYLACETYLGLUTAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15004 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15050977/ |
3.75 g/m² single, intravenous dose: 3.75 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: SODIUM BENZOATE |
PHENYLACETIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
28156 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15050977/ |
5.5 g/m² single, intravenous dose: 5.5 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: SODIUM BENZOATE |
PHENYLACETIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2047 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15050977/ |
3.75 g/m² single, intravenous dose: 3.75 g/m² route of administration: Intravenous experiment type: SINGLE co-administered: SODIUM BENZOATE |
PHENYLACETYLGLUTAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.44% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8946671/ |
SODIUM PHENYLACETATE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Disc. AE: Metabolic acidosis, Injection site reactions... AEs leading to discontinuation/dose reduction: Metabolic acidosis (< 1%) Sources: Page: p.11Injection site reactions (< 1%) Bradycardia (0.32%) Abdominal distension (0.32%) Injection site extravasation (0.32%) Hemorrhage injection site (0.32%) Blister (0.32%) Subdural hematoma (0.32%) Hyperammonemia (0.32%) Hypoglycemia (0.32%) Clonus (0.32%) Coma (0.32%) Increased intracranial pressure (0.32%) Hypercapnia (0.32%) Kussmaul respiration (0.32%) Respiratory distress (0.32%) Respiratory failure (0.32%) Pruritis (0.32%) Maculo-papular rash (0.32%) |
300 mg/kg 1 times / day multiple, intravenous (max) Recommended Dose: 300 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 300 mg/kg, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.8Arginine HCl, i.v(200-600 mg/kg) |
unhealthy Health Status: unhealthy Condition: Cancer Sources: Page: p.8 |
Other AEs: Neurotoxicity... Other AEs: Neurotoxicity Sources: Page: p.8 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal distension | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Blister | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Bradycardia | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Clonus | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Coma | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Hemorrhage injection site | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Hyperammonemia | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Hypercapnia | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Hypoglycemia | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Increased intracranial pressure | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Injection site extravasation | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Kussmaul respiration | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Maculo-papular rash | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Pruritis | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Respiratory distress | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Respiratory failure | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Subdural hematoma | 0.32% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Injection site reactions | < 1% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Metabolic acidosis | < 1% Disc. AE |
5.5 g/m2 1 times / day multiple, intravenous Recommended Dose: 5.5 g/m2, 1 times / day Route: intravenous Route: multiple Dose: 5.5 g/m2, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.11Arginine HCl, i.v(200-600 mg/kg) |
unhealthy, 0 - 53 n = 316 Health Status: unhealthy Condition: Hyperammonemia Age Group: 0 - 53 Sex: M+F Population Size: 316 Sources: Page: p.11 |
Neurotoxicity | 300 mg/kg 1 times / day multiple, intravenous (max) Recommended Dose: 300 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 300 mg/kg, 1 times / day Co-administed with:: Sodium Benzoate, i.v(5.5 g/m2) Sources: Page: p.8Arginine HCl, i.v(200-600 mg/kg) |
unhealthy Health Status: unhealthy Condition: Cancer Sources: Page: p.8 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203284Orig1s000PharmR.pdf#page=26 Page: 26.0 |
PubMed
Title | Date | PubMed |
---|---|---|
[Studies on the immobilized penicillin acylase on polymer beads]. | 2001 Apr |
|
[Determination of degraded products of penicillin by high performance liquid chromatography]. | 2001 Jan |
|
[Determination of organic acids in cigarette smoke]. | 2001 Jul |
|
Correlation between microbial enzyme activities in the rumen fluid of sheep under different treatments. | 2001 Nov-Dec |
|
Aromatic amino acid biosynthesis and production of related compounds from p-hydroxyphenylpyruvic acid by rumen bacteria, protozoa and their mixture. | 2002 |
|
Evaluation of strains derived from Escherichia coli W as hosts for the expression of penicillin G-acylase-encoding gene cloned on the recombinant plasmid pKA18. | 2002 |
|
Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. | 2002 Apr |
|
The role of hydrophobic active-site residues in substrate specificity and acyl transfer activity of penicillin acylase. | 2002 Apr |
|
New glycosides from the Japanese fern Hymenophyllum barbatum. | 2002 Apr |
|
Aponecrotic, antiangiogenic and antiproliferative effects of a novel dextran derivative on breast cancer growth in vitro and in vivo. | 2002 Apr |
|
Effects of cryopreservation and phenylacetate on biological characters of adherent LAK cells from patients with hepatocellular carcinoma. | 2002 Apr |
|
Fermentation of cottonseed and other feedstuffs in cattle rumen fluid. | 2002 Apr 10 |
|
Application of molecular genetics to the diagnosis of lymphoid-rich effusions: study of 95 cases with concomitant immunophenotyping. | 2002 Aug |
|
Identification of bacteria in drinking and purified water during the monitoring of a typical water purification system. | 2002 Aug 15 |
|
Genomic analysis of the aromatic catabolic pathways from Pseudomonas putida KT2440. | 2002 Dec |
|
Neonatal presentation of ventricular tachycardia and a Reye-like syndrome episode associated with disturbed mitochondrial energy metabolism. | 2002 Dec 30 |
|
4-Fluoro-N-butylphenylacetamide: a synthetic phenylacetate derivative that upregulates Bcl-X(S), activates caspase cascade and induces apoptosis in human squamous lung cancer CH27 cells. | 2002 Dec 5 |
|
Pheromone components of the wheat stem sawfly: identification, electrophysiology, and field bioassay. | 2002 Feb |
|
Studies on a soft glycopyrrolate analog, SG-1. | 2002 Feb |
|
Investigations into tumor accumulation and peroxisome proliferator activated receptor binding by F-18 and C-11 fatty acids. | 2002 Feb |
|
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. | 2002 Feb 1 |
|
Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides. | 2002 Feb 25 |
|
Growth inhibition of human melanoma tumor cells by the combination of sodium phenylacetate (NaPA) and substituted dextrans and one NaPA-dextran conjugate. | 2002 Jan |
|
[Penicillin G acylase--synthesis, regulation, production]. | 2002 Jan |
|
The cefT gene of Acremonium chrysogenum C10 encodes a putative multidrug efflux pump protein that significantly increases cephalosporin C production. | 2002 Jul |
|
Molecular analysis of aerobic phenylacetate degradation in Azoarcus evansii. | 2002 Jul |
|
Polarization IR spectra of the hydrogen bond in phenylacetic acid crystals: H/D isotopic effects temperature and polarization effects. | 2002 Jul |
|
Monitoring of enzymatic hydrolysis of penicillin G by pyrolysis-negative ion mass spectrometry. | 2002 Jul 1 |
|
Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans. | 2002 Jun |
|
Immunosuppressant-like effects of phenylbutyrate on growth inhibition of Saccharomyces cerevisiae. | 2002 Jun |
|
[Up regulation of phenylacetate to glioma homeobox gene expression]. | 2002 Mar |
|
Emended descriptions of the genus Micrococcus, Micrococcus luteus (Cohn 1872) and Micrococcus lylae (Kloos et al. 1974). | 2002 Mar |
|
Induction and repression of the sty operon in Pseudomonas putida CA-3 during growth on phenylacetic acid under organic and inorganic nutrient-limiting continuous culture conditions. | 2002 Mar 5 |
|
Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. | 2002 May |
|
Identification of phenyldecanoic acid as a constituent of triacylglycerols and wax ester produced by Rhodococcus opacus PD630. | 2002 May |
|
Characterization of tropane alkaloid aromatic esters that reverse the multidrug-resistance phenotype. | 2002 May-Jun |
|
Metabolic physiology of aroma-producing Kluyveromyces marxianus. | 2002 Nov |
|
A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects. | 2002 Nov-Dec |
|
Arginine 165/arginine 277 pair in (S)-mandelate dehydrogenase from Pseudomonas putida: role in catalysis and substrate binding. | 2002 Oct 15 |
|
beta-Cell adaptation to insulin resistance. Increased pyruvate carboxylase and malate-pyruvate shuttle activity in islets of nondiabetic Zucker fatty rats. | 2002 Oct 18 |
|
Development and substantiation of a liquid chromatographic method for monitoring organic reactions involved in synthesis of 4-methoxyphenylacetic acid. | 2002 Oct 4 |
|
Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy. | 2002 Sep |
|
[Treatment of methicillin-resistant Staphylococcus aureus (MRSA) as part of biosurgical management of a chronic leg ulcer]. | 2002 Sep |
|
Aerobic metabolism of phenylacetic acids in Azoarcus evansii. | 2002 Sep |
|
Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. | 2003 Apr |
|
Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. | 2003 Feb |
|
Potent sigma 1-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine provides ischemic neuroprotection without altering dopamine accumulation in vivo in rats. | 2003 Feb |
|
Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. | 2003 Feb 10 |
|
Environmental effects caused by olive mill wastewaters: toxicity comparison of low-molecular-weight phenol components. | 2003 Feb 12 |
|
Dual stereoselectivity of 1-(2'-carboxy)benzyl 2-deoxyglycosides as glycosyl donors in the direct construction of 2-deoxyglycosyl linkages. | 2003 Jan 27 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:18:30 GMT 2023
by
admin
on
Fri Dec 15 15:18:30 GMT 2023
|
Record UNII |
ER5I1W795A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 172.515
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
||
|
DEA NO. |
8791
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
||
|
NDF-RT |
N0000175807
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
||
|
FDA ORPHAN DRUG |
267408
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
||
|
NDF-RT |
N0000175806
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
||
|
JECFA EVALUATION |
PHENYLACETIC ACID
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
||
|
DEA NO. |
8791
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
||
|
FDA ORPHAN DRUG |
189804
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C77487
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
5010
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
PHENYLACETIC ACID
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
100000172583
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
C025136
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
1699049
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
103-82-2
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
DB09269
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
ER5I1W795A
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
30745
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
203-148-6
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
999
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
C45678
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
CONCEPT | Industrial Aid | ||
|
ER5I1W795A
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
4624
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
DTXSID2021656
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
33332
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | RxNorm | ||
|
C1613
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
ALTERNATIVE | |||
|
m8650
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | Merck Index | ||
|
940
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY | |||
|
125718
Created by
admin on Fri Dec 15 15:18:31 GMT 2023 , Edited by admin on Fri Dec 15 15:18:31 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
The active molecule that combines with glutamine (an amino acid with two nitrogen molecules) to form phenylacetylglutamine which is rapidly excreted by the kidneys and does not require metabolism via the urea cycle. Phenylbutyrate thus provides an “ammonia sink”, an alternative pathway for excretion of excess nitrogen and ammonia. The active metabolite phenylacetate is also effective therapeutically, but has a disagreeable odor and taste that affect compliance and acceptability.
|
||
|
PARENT -> METABOLITE |
|
||
|
PARENT -> METABOLITE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
impurity D at 210 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|